



5/17/04

GP-1617

EXPRESS MAIL LABEL NO. EV 333 997 542 US

| | | |
|---|----------------------|----------------------|
| AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT Address to: Commissioner of Patents and Trademarks Washington, D.C. 20231 | Application No. | 10/049,556 |
| | Confirmation No. | 7597 |
| | Filing Date | May 7, 2002 |
| | First Named Inventor | LITTLE, DAVID GRAHAM |
| | Examiner | CRIARES, THEODORE J. |
| | Group Art Unit | 1617 |
| | DOCKET NO. | NPAG-001 |

Sir:

This is in response to the Restriction Requirement dated April 14, 2004. This paper also presents amendments to the claims.

AMENDMENTS

Please amend claims 48, 54 and 63, and cancel claims 62, 67-71 and 81-83 as follows:

1.-47. (Cancelled)

48. (Currently Amended) A method for treating a fractured bone, the method ~~including comprising~~ administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.

49. (Previously Presented) The method of claim 48 wherein the drug is administered to the subject as a single dose.

50. (Previously Presented) The method of claim 49 wherein the single dose of drug is administered at an early stage of treatment of the fractured bone.

51. (Previously Presented) The method of claim 48 wherein the mode of administration is as a perioperative intravenous infusion.

52. (Previously Presented) The method of claim 48 wherein the mode of administration is oral.

53. (Previously Presented) The method of claim 48 wherein the mode of administration is transdermal.

54. (Currently Amended) ~~A method of treating a fractured bone, the method including the steps of:~~ The method of claim 48 further comprising

(a) ~~administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate; and~~

(b) providing a vibratory stimulus to the fractured bone.

55. (Previously Presented) The method of claim 54 wherein the vibratory stimulus is provided by ultrasound stimulation or vibration stimulation.

56. (Previously Presented) The method of claim 54 wherein the vibratory stimulus includes

periodically providing a vibratory stimulus at the resonant frequency of the bone.

57. (Previously Presented) The method of claim 55 wherein the vibratory stimulus includes periodically providing a vibratory stimulus at the resonant frequency of the bone.

58. (Previously Presented) The method of claim 56 wherein the resonant frequency is calculated as a function of the bone's vibratory response to the vibratory stimulus.

59. (Previously Presented) The method of claim 54 wherein the vibratory stimulus is provided at a late stage in the treatment of the fractured bone.

60. (Previously Presented) The method of claim 54 wherein the step of providing a vibratory stimulus is concurrent with the step of administering a therapeutically effective amount of the drug.

61. (Previously Presented) The method of claim 60 wherein the vibratory stimulus is provided and the therapeutically effective amount of the drug is administered at an early stage in the treatment of a fractured bone.

62. (Cancelled)

63. (Currently Amended) A method for promoting new bone formation at a fracture site in a subject suffering from delayed union of a fracture, the method including comprising administering to the subject a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.

64. (Previously Presented) The method of claim 63 wherein the at least one bisphosphonate is administered parenterally as a single dose at or near the time of surgery.

65. (Previously Presented) The method of claim 64 wherein a further parenteral dose of the at least one bisphosphonate is administered about four to six weeks after the initial dose.

66. (Previously Presented) The method of claim 64 wherein further oral doses of the at least one bisphosphonate are administered in a daily or second daily regimen commencing about four to six weeks after the initial dose for a period of about two months or until sufficient new bone has been formed.

67. – 71. (Cancelled)

72. (Previously Presented) The method of claim 48 wherein the therapeutically effective amount of drug promotes new bone formation at the fracture site.

73. (Previously Presented) The method of claim 48 wherein the drug is Zoledronate.

74. (Previously Presented) The method of claim 48 wherein the drug is a combination of two or more bisphosphonates.

75. (Previously Presented) The method of claim 54 wherein the therapeutically effective amount of drug promotes new bone formation at the fracture site.

76. (Previously Presented) The method of claim 54 wherein the drug is Zoledronate.

77. (Previously Presented) The method of claim 54 wherein the drug is a combination of two or more bisphosphonates.

78. (Previously Presented) The method of claim 63 wherein the therapeutically effective amount of drug promotes new bone formation at the fracture site.

79. (Previously Presented) The method of claim 63 wherein the drug is Zoledronate.

80. (Previously Presented) The method of claim 63 wherein the drug is a combination of two or more bisphosphonates.

81. – 83. (Cancelled)